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solutions for the long dwell. In contrast, we compared
icodextrin with glucose 1.36% in patients without clini-
cal signs of overhydration, of whom the great majority
had significant residual renal function (mean rGFR at
start 4.8 ± 3.2 mL/min). At that time, 1.36% solutions
were used in our clinics for the long dwell in patients in
patients with significant residual diuresis without clinical
signs of overhydration.
In search for an explanation for the discrepancies be-
tween the two studies, we hypothesized that icodextrin
might have led to underhydration in some of our patients.
Therefore, we compared the decline in rGFR between pa-
tients whom were underhydrated at the end of the study
and those who were not. Underhydration was defined as
a normalized ECW (ECW:height) below the 10th per-
centile of the stable renal transplant patients studied in
[1] [<7.8 L/m in males and <7.0 L/m in females].
Four of the 19 patients in the icodextrin-treated group
who completed the study fulfilled this criterion. Com-
pared to the 13 patients treated with icodextrin who were
not underhydrated after completion of the study, the fall
in rGFR tended to be larger [−3.2 ± 2.4 mL/min vs −1.0
± 1.6 mL/min; P = 0.055]. When the underhydrated pa-
tients were excluded from analysis, the decline in rGFR
between patients treated with icodextrin and the control
group was comparable [−1.0 ± 1.6 vs –0.6 ± 0.8 mL/min;
P = 0.6].
In conclusion, the decline in rGFR observed in our
previous study after treatment with icodextrin may have
been due to underhydration in a minority of patients.
Given the limited number of patients in whom underhy-
dration was diagnosed, this assumption needs to be con-
firmed. However, when using icodextrin in patients with
significant residual renal function without clinical signs of
overhydration, objective assessment of fluid status may
be helpful in defining treatment targets [4].
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Arterial stiffness in patients
with kidney transplantation
To the Editor: We read the recent article by Bahous et
al demonstrating tobacco consumption and acute rejec-
tion modulates both aortic stiffness and renal functional
deterioration after kidney transplantation [1]. We wish to
raise several points that can be considered.
Primary end points, including doubling serum creati-
nine (4 patients) and/or new cardiovascular events (9 pa-
tients), which are both independent situations resulting
from different factors, seem to be confusing. In this study
design, one cannot properly expect that the pulse wave
velocity (PWV), mean 54.1 months after the transplan-
tation, can be used as an indicator of the cardiovascular
disease (CVD) after the transplantation. We do not know
the level of PWV before the transplantation; the patients
dying after the transplantation did not have the results
(12 patients), which could affect the analysis. Also, 9 pa-
tients had new CVD, and 6 of them had previous CVD.
It could have been important to see these patients’ PWV
results (9 patients). It is not logical to take serum crea-
tinine into analysis of primary end points (according to
the definition of primary end points). However, it could
be interesting to see whether kidney function, as a risk
factor for CVD, might be also a risk factor for CVD after
the transplantation [2].
Tobacco consumption was given in Table 1. However,
how many patients were using tobacco in both groups?
How many of them were ex-smokers or recent smokers?
The mean pack-year given in Table 1 demonstrated how
many patients?
Also, in Table 2, transplant age (months) was given as
mean 54.1 ± 29.2 for entire, mean 42.5 ± 18.2 for subjects
with positive end points, mean 38 ± 13.5 for patients with
negative end points. It should be corrected.
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